Observational studyNature communications2021
In vivo inducible reverse genetics in patients' tumors to identify individual therapeutic targets.
Open access · goldAbstract readObservational Study
In one paragraph
Observational study in Nature communications, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
1.5field-weighted citation impact, top 18% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 21 citations in OpenAlex.
- A platform of serially transplantable AML PDX models covering subgroups for which no cell lines exist.HemaSphere · 2026Article
- Enhancer Hijacking Discovery in Acute Myeloid Leukemia by Pyjacker Identifies MNX1 Activation via Deletion 7q.Blood cancer discovery · 2025Article
- PDX models for functional precision oncology and discovery science.Nature reviews. Cancer · 2025Review
- RanBALL: An Ensemble Random Projection Model for Identifying Subtypes of B-Cell Acute Lymphoblastic Leukemia.bioRxiv : the preprint server for biology · 2025Article
- Advances in the application of patient-derived xenograft models in acute leukemia resistance.Cancer drug resistance (Alhambra, Calif.) · 2025Review
- DUX4-r exerts a neomorphic activity that depends on GTF2I in acute lymphoblastic leukemia.Science advances · 2023Article
- Combined proteomics and CRISPR‒Cas9 screens in PDX identify ADAM10 as essential for leukemia in vivo.Molecular cancer · 2023Article
- Dissecting metastasis using preclinical models and methods.Nature reviews. Cancer · 2023Review
- Patient-derived xenograft models in cancer therapy: technologies and applications.Signal transduction and targeted therapy · 2023Review
- X-linked inhibitor of apoptosis protein represents a promising therapeutic target for relapsed/refractory ALL.EMBO molecular medicine · 2023Article
- The regulatory role of Pin1 in neuronal death.Neural regeneration research · 2023Review
- ROS responsive polyethylenimine-based fluorinated polymers for enhanced transfection efficiency and lower cytotoxicity.Bosnian journal of basic medical sciences · 2022Article
- Prime-seq, efficient and powerful bulk RNA sequencing.Genome biology · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
27 authors at 8 institutions in 1 country.
Michela Carlet *Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.
Kerstin Völse *Research Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.
Jenny VergalliResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.
Martin BeckerResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.
Tobias HeroldResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.ORCID 0000-0002-9615-9432
Anja ArnerDepartment of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig Maximilian University (LMU), Munich, Germany.
Daniela SenftResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.
Vindi JurinovicResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.
Wen-Hsin LiuResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.
Yuqiao GaoResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.
Veronika DillClinic and Policlinic for Internal Medicine III, Technical University of Munich, School of Medicine, Munich, Germany.
Boris FehseResearch Department Cell and Gene Therapy, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0001-9780-7211
Claudia D BaldusInternal Medicine II, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.
Lorenz BastianInternal Medicine II, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Campus Kiel, Kiel, Germany.ORCID 0000-0002-1487-9437
Lennart LenkDepartment of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.
Denis M ScheweDepartment of Pediatrics I, ALL-BFM Study Group, Christian-Albrechts University Kiel and University Medical Center Schleswig-Holstein, Kiel, Germany.ORCID 0000-0002-1070-0217
Johannes W BagnoliAnthropology and Human Genomics, Faculty of Biology, Ludwig Maximilian University (LMU), Munich, Germany.
Binje VickResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.ORCID 0000-0003-1956-2778
Jan Philipp SchmidResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany.
Alexander WilhelmInstitute of Pharmaceutical Biology, Diagnosic Center of Acute Leukemias (DCAL), Goethe-University, Frankfurt/Main, Germany.
Rolf MarschalekInstitute of Pharmaceutical Biology, Diagnosic Center of Acute Leukemias (DCAL), Goethe-University, Frankfurt/Main, Germany.ORCID 0000-0003-4870-3445
Philipp J JostGerman Cancer Consortium (DKTK), Partnering Site Munich, Munich, Germany.
Cornelius MiethingDepartment of Medicine I, Medical Center, University of Freiburg, Faculty of Medicine, Freiburg, Germany.ORCID 0000-0003-4699-3805
Kristoffer RieckenResearch Department Cell and Gene Therapy, Department of Stem Cell Transplantation, University Medical Center Hamburg-Eppendorf, Hamburg, Germany.ORCID 0000-0001-9050-6766
Marc Schmidt-SupprianInstitute of Experimental Hematology, Technical University of Munich, Munich, Germany.
Vera BinderDepartment of Pediatrics, Dr. von Hauner Children's Hospital, University Hospital, Ludwig Maximilian University (LMU), Munich, Germany.
Irmela JeremiasResearch Unit Apoptosis in Hematopoietic Stem Cells, Helmholtz Zentrum München, German Research Center for Environmental Health (HMGU), Munich, Germany. Irmela.Jeremias@helmholtz-muenchen.de.ORCID 0000-0003-1773-7677
Helmholtz Zentrum München · DEChristian-Albrechts-Universität zu Kiel · DELudwig-Maximilians-Universität München · DEGoethe University Frankfurt · DETechnical University of Munich · DEUniversität Hamburg · DETUM Klinikum · DEUniversity of Freiburg · DE
Funding
No grant is acknowledged in the PubMed record.
Abstract
High-throughput sequencing describes multiple alterations in individual tumors, but their functional relevance is often unclear. Clinic-close, individualized molecular model systems are required for functional validation and to identify therapeutic targets of high significance for each patient. Here, we establish a Cre-ER
Indexed as
Adaptor Proteins, Signal TransducingAdultAnimalsAntineoplastic AgentsBiomarkers, TumorChildFemaleGene SilencingHomeodomain ProteinsHumansLeukemia, Myeloid, AcuteMaleMiceMyeloid Cell Leukemia Sequence 1 ProteinMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, FusionAdaptor Proteins, Signal TransducingAntineoplastic AgentsBiomarkers, TumorDDIT4L protein, humanDUX4L1 protein, humanHomeodomain ProteinsMCL1 protein, humanMLL-AF4 fusion protein, humanMyeloid Cell Leukemia Sequence 1 ProteinMyeloid-Lymphoid Leukemia ProteinOncogene Proteins, Fusion
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.